Search

Your search keyword '"Mahe, B."' showing total 162 results

Search Constraints

Start Over You searched for: Author "Mahe, B." Remove constraint Author: "Mahe, B."
162 results on '"Mahe, B."'

Search Results

2. Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia

4. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

5. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

8. P56 - Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation: COMPARABLE OUTCOMES AMONG ADULT PATIENTS ALLOTRANSPLANTED FOR MYELODYSPLASTIC SYNDROME USING HAPLOIDENTICAL, MATCHED UNRELATED OR MATCHED SIBLING DONORS: A SINGLE-CENTER STUDY.

10. Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation

19. Long-term follow-up of a randomized trial of fludarabine–mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies

20. Fourth meeting of the European Neurological Society 25–29 June 1994 Barcelona, Spain: Abstracts of Symposia and free communications

23. PF614 PATIENT-REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB-RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)

24. PS1046 FLT3 LIGAND PLASMA LEVELS HAVE NO IMPACT ON OUTCOMES AFTER ALLOTRANSPLANT IN ACUTE LEUKEMIA

25. PATIENT-REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB-RITUXIMAB IN THE INNOVATE STUDY

26. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study

29. Phase 3 trial of Ibrutinib plus rituximab in Waldenstrom's macroglobulinemia

35. Bing-Neel syndrome, a rare complication of Waldenstrom macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).

36. Digital concentration gradient generators on a microfluidic chip

40. Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors

41. Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

42. RBC Transfusions and Iron Chelation Therapy in Clinical Practice in MDS: A One Month Survey by the GFM.

44. Thalidomide for the Treatment of Low Risk Myelodysplasia.

45. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group

48. PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma.

49. Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma.

Catalog

Books, media, physical & digital resources